4//SEC Filing
Dake Benjamin T 4
Accession 0001415889-24-011252
CIK 0001798749other
Filed
Apr 18, 8:00 PM ET
Accepted
Apr 19, 6:00 PM ET
Size
12.6 KB
Accession
0001415889-24-011252
Insider Transaction Report
Form 4
Dake Benjamin T
See Remarks
Transactions
- Sale
Common Stock
2024-04-17$23.97/sh−68$1,630→ 1,291 total - Exercise/Conversion
Common Stock
2024-04-17$2.14/sh+6,853$14,665→ 8,144 total - Sale
Common Stock
2024-04-17$22.32/sh−6,447$143,865→ 1,697 total - Sale
Common Stock
2024-04-17$23.17/sh−338$7,831→ 1,359 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-04-17−6,853→ 95,936 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (6,853 underlying)
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.812 to $22.80, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.825 to $23.65, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.
Documents
Issuer
Aerovate Therapeutics, Inc.
CIK 0001798749
Entity typeother
Related Parties
1- filerCIK 0001869248
Filing Metadata
- Form type
- 4
- Filed
- Apr 18, 8:00 PM ET
- Accepted
- Apr 19, 6:00 PM ET
- Size
- 12.6 KB